Breaking News

Samsung Introduces Its Latest Radiology Innovations at RSNA 2020

Samsung to highlight its medical imaging portfolio with its latest radiology innovations in ultrasound, digital radiography and mobile computed tomography.

C360 Spine Portfolio Unveiled -NuVasive Advises Launch Represents a Significant Opportunity for Growth As Cervical Spine Procedures Comprise An Approximately $2.6 Bil Segment of the Global Spine Market

"C360 spine portfolio unveiling reflects NuVasive's commitment to deliver innovative technology for the anterior and posterior cervical spine designed to improve the quality of care even in the most established area of spine," said Massimo Calafiore, executive vice president, Global Business Units at NuVasive.

Novel Biosynthetic Tissue Valve 6 Month Clinical Results Reported

Six-month data for 16 patients enrolled across three sites in the United States were presented in a moderated poster session during the American Heart Association Virtual Scientific Sessions from November 13-17, 2020. The poster, P148, is titled, Early Results of a Novel ePTFE-based Pulmonary Valved Conduit in a Pediatric Patient Population.

Retinal-imaging Breakthrough That Can Swiftly Detect Eye Diseases

European researchers are developing a new real-time scanner that will create a full image of a moving eye without any blurring. Teaming up with photonics innovation hub ACTPHAST 4R the scientists at Vrije Universiteit (VU) Amsterdam are progressing their scanner concept to a demonstrator stage to acquire data faster than existing optical imaging technologies.  

Ajax Health Appoints HealthQuest Managing Partner Garheng Kong as Chairman

Dr. Garheng Kong, MD, Ph.D., MBA, Managing Partner of HealthQuest Capital (“HealthQuest”) has been appointed Chairman of the Board of Directors of Ajax Health.

Ajax is a company focused on developing and accelerating high-growth companies in medtech, healthcare services and healthcare IT that focus on truly innovative approaches to solving major issues in healthcare. HealthQuest, a healthcare-focused growth equity investor, is the longstanding capital partner of Ajax and most recently led the financings of Ajax 2 and Ajax 3, two investment vehicles raised in 2019.

Ajax 2 is currently developing Ablacon, an AI-driven mapping system to guide the treatment of atrial fibrillation; Cortica, a provider of advanced therapies for autism and neurodevelopment; and EP Map, a 3-D mapping system for use in electrophysiology procedures. Ajax 3 is currently developing Protaryx Medical, a company developing a first-in-class cardiac device for transseptal access to the left atrium; Verix Health, a platform of steerable devices enabling minimally invasive delivery of diagnostic and therapeutic tools; and Bronx Medical, a device spinout of Verix that specifically targets interventional pulmonology.

“Garheng Kong and HealthQuest have been invaluable partners to Ajax since our inception and have provided much more than capital alone. Their insight as healthcare investors spans across healthcare modalities, and their understanding of later-stage operation and commercialization greatly enables the Ajax model of laser-focused execution in bringing our companies to exit,” said Duke Rohlen, Founder, CEO and Managing Director of Ajax Health. “We are thrilled to have Garheng’s oversight as Chairman, and believe this is a natural extension of our partnership and in line with how Ajax and HealthQuest have worked together to date.”

A physician, scientist, and engineer by training, Dr. Kong has over two decades of experience investing in innovative healthcare companies with a long list of successes (20+ IPO/M&A exits). He also serves on the boards of LabCorp (LH), Alimera Sciences (ALIM), StrongBridge (SBBP), Be The Match, and the Duke University Medical Center and is an Aspen Institute Health Innovators Fellow and Kauffman Fellows Mentor. Dr. Kong holds an MBA, MD and PhD from Duke University, and two BS degrees from Stanford University.

“We’ve been continually impressed by Duke and his team since partnering with them in 2016 on their development of device company Spirox (and sale to Entellus), and through the evolution of the Ajax Health platform. They are world-class operators with a proven ability to repeatedly identify and accelerate unique high-potential health tech assets,” said Dr. Kong.

Latest Posts

Samsung Introduces Its Latest Radiology Innovations at RSNA 2020

Samsung to highlight its medical imaging portfolio with its latest radiology innovations in ultrasound, digital radiography and mobile computed tomography.

C360 Spine Portfolio Unveiled -NuVasive Advises Launch Represents a Significant Opportunity for Growth As Cervical Spine Procedures Comprise An Approximately $2.6 Bil Segment of the Global Spine Market

"C360 spine portfolio unveiling reflects NuVasive's commitment to deliver innovative technology for the anterior and posterior cervical spine designed to improve the quality of care even in the most established area of spine," said Massimo Calafiore, executive vice president, Global Business Units at NuVasive.

LuminUltra Acquires Source Molecular Corporation – To Expands Testing Capacity Including Range of COVID-19 Offerings

LuminUltra has acquired Source Molecular Corporation, a leader in lab-based testing solutions for microbial source tracking of pathogens including SARS-CoV-2, the virus that causes COVID-19.

Don't Miss

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials. 

Stoke Therapeutics Announces Proposed Public Offering

November 18, 2020 Stoke Therapeutics, Inc., a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein...

TissueCypher Barrett’s Esophagus Assay Confirm the Ability to Identify Patients at High Risk for Progression to Cancer

TissueCypher Barrett’s Esophagus Assay independent peer-reviewed studies, are authored by Prof. Jacques Bergman and Dr. Nicola Frei (University Medical Center, Amsterdam, the Netherlands).